Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Fuji
UBS
Covington
McKesson

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,251,910

« Back to Dashboard

Summary for Patent: 6,251,910
Title: 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Abstract:Compounds of formula having the following stereochemistry ##STR1## wherein R, R.sup.1, R.sub.2, R.sup.3 and R.sup.4 are as defined in the specification. The compounds are useful as P.sub.2T receptor antagonists.
Inventor(s): Guile; Simon (Loughborough, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (Nottingham, GB)
Assignee: AstraZeneca UK Limited (London, GB)
Application Number:09/155,023
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,251,910
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,251,910
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 6,251,910

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,251,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9702773Jul 22, 1997
PCT Information
PCT FiledJuly 15, 1998PCT Application Number:PCT/SE98/01393
PCT Publication Date:February 04, 1999PCT Publication Number: WO99/05143

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
QuintilesIMS
Cantor Fitzgerald
Fuji
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.